Stockscreener 앱 받기
82.35
4.62%
3.64
Soleno Therapeutics Inc 주식(SLNO)의 최신 뉴스
Regression Model Predicts Rangebound Movement in Soleno Therapeutics Inc.High Growth Low Risk Stock Selection Gets Analyst Nod - metal.it
Soleno signals $500M cash war chest and robust Vykat XR launch trajectory while advancing EU expansion - MSN
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Q2 2025 Earnings Call Transcript - Insider Monkey
Soleno Therapeutics’ Earnings Call Highlights Success and Optimism - TipRanks
Stifel raises Soleno Therapeutics stock price target to $118 on strong launch - Investing.com Nigeria
Soleno Therapeutics price target raised to $120 from $115 at TD Cowen - TipRanks
Guggenheim raises Soleno Therapeutics stock price target to $106 on strong sales By Investing.com - Investing.com South Africa
Guggenheim raises Soleno Therapeutics stock price target to $106 on strong sales - Investing.com Australia
Earnings call transcript: Soleno Therapeutics beats Q2 2025 forecasts with strong revenue - Investing.com
Soleno Therapeutics Q2 2025: Key Contradictions in Time to Fill and Revenue Growth Expectations - AInvest
Soleno (SLNO) Q2 Revenue Jumps 30% - AOL.com
Soleno Therapeutics Reports Strong Q2 2025 Performance - TipRanks
Soleno Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Transcript : Soleno Therapeutics, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Strong Buy Recommendation for Soleno Therapeutics Driven by Impressive Vykat XR Launch and Market Demand - TipRanks
Soleno (SLNO) Q2 Revenue Jumps 30% - The Motley Fool
SOLENO THERAPEUTICS INC SEC 10-Q Report - TradingView
Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Soleno Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Soleno Therapeutics earnings beat by $0.55, revenue topped estimates - Investing.com Canada
Soleno reports $32.7 million in Q2 revenue from VYKAT XR launch By Investing.com - Investing.com South Africa
Soleno reports $32.7 million in Q2 revenue from VYKAT XR launch - Investing.com Nigeria
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results - The Manila Times
Soleno Therapeutics Q2 2025 Financial Results and VYKAT XR Launch Update - TradingView
Soleno Therapeutics Q2 net loss $4.7 mln - MarketScreener
Soleno Therapeutics Provides Update on U.S. Launch of - GlobeNewswire
Earnings Flash (SLNO) Soleno Therapeutics, Inc. Reports Q2 Revenue $32.7M, vs. FactSet Est of $25.1M - MarketScreener
Soleno Reports First Revenue Quarter: VYKAT XR Launch Draws 295 Prescribers in 90 Days - Stock Titan
When Will Soleno Therapeutics, Inc. (NASDAQ:SLNO) Become Profitable? - 富途牛牛
Is Soleno Therapeutics Inc. a growth stock or a value stockDiscover undervalued opportunities early - Jammu Links News
When is Soleno Therapeutics Inc. stock expected to show significant growthDynamic investment opportunities - Jammu Links News
Is Soleno Therapeutics Inc. a good long term investmentCapitalize on market trends before they peak - Jammu Links News
What makes Soleno Therapeutics Inc. stock price move sharplyHigh-impact investment strategies - Jammu Links News
What are analysts’ price targets for Soleno Therapeutics Inc. in the next 12 monthsUnmatched market gains - Jammu Links News
How does Soleno Therapeutics Inc. compare to its industry peersRealize exceptional returns through smart trading - Jammu Links News
What is the risk reward ratio of investing in Soleno Therapeutics Inc. stockCapitalize on momentum-driven investment opportunities - Jammu Links News
Should I hold or sell Soleno Therapeutics Inc. stock in 2025Maximize gains with proven stock analysis - Jammu Links News
What are the latest earnings results for Soleno Therapeutics Inc.Unlock powerful portfolio management tools - Jammu Links News
How does Soleno Therapeutics Inc. generate profit in a changing economyExplosive trading growth - Jammu Links News
Soleno Therapeutics Inc. Stock Analysis and ForecastMaximize returns with expert trading insights - Jammu Links News
What catalysts could drive Soleno Therapeutics Inc. stock higher in 2025Stay ahead with daily market updates - Jammu Links News
What analysts say about Soleno Therapeutics Inc. stockMaximize gains with proven stock analysis - Jammu Links News
What machine learning models say about Soleno Therapeutics Inc.Fast Gaining Stock Screener Reports Released - metal.it
How Soleno Therapeutics Inc. stock performs during market volatilityWeekly Watchlist of High Movers Released - beatles.ru
Live Scanner Shows Breakout on Soleno Therapeutics Inc.Growth Based Investment Plan Guidance Highlighted - metal.it
Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET - The Globe and Mail
What does SLNO's flat EPS in 2024 indicate for future growth? - AInvest
Are analysts optimistic about SLNO's EPS turnaround? - AInvest
Can Soleno reverse its negative revenue trend? - AInvest
Soleno Therapeutics to Release Q2 2025 Financial Results and Operational Highlights - AInvest
Published on: 2025-07-28 20:12:42 - metal.it
0.24%
3.39%
자본화:
|
볼륨(24시간):